Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home › News › News archive › Gamida, Teva get FDA fast-track status for StemEx

Gamida, Teva get FDA fast-track status for StemEx

Gamida Cell said its joint venture with Teva Pharmaceutical Industries has gained FDA fast-track status for the development of StemEx.

StemEx is a stem cell treatment being tested as an alternative to a bone marrow transplant among patients with leukemia, lymphoma or other blood cancers. The product uses umbilical-cord-blood cells.

Source: Globes

Document Actions
Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...

Submit a news item!

News

Partners in the Cluster can submit news items to be circulated widely via the homepage of the Amsterdam BioMed Cluster.

Or add us to your mailing list for press releases: info[at]amsterdambiomed.nl

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster